Aberdeen Group plc cut its stake in Vertex Pharmaceuticals by 16.8%, now holding 262,057 shares valued at $118.81 million. In contrast, several institutional investors increased their shares, while Vertex reported Q4 earnings of $5.03 per share and $3.19 billion in revenue.

NodeGuardian

2026-04-16 06:00:55

Abstract generation in progress

Aberdeen Group plc decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.8% in the fourth quarter, reducing its holdings to 262,057 shares worth $118.81 million. Despite this, other institutional investors like Vanguard Group Inc., Capital Research Global Investors, and Capital International Investors significantly increased their positions in the pharmaceutical company. Vertex Pharmaceuticals reported Q4 earnings of $5.03 per share, missing estimates slightly, with revenue reaching $3.19 billion.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes

Reward
1
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
139.48K Popularity
#
CryptoMarketRecovery
93.44K Popularity
#
US-IranTalksVSTroopBuildup
764.76K Popularity
#
USStocksHitRecordHighs
1.19M Popularity
#
WCTCTradingChallengeShare8MUSDT
622.34K Popularity

Sitemap

Aberdeen Group plc Has $118.81 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Trending Topics

GatePreIPOsLaunchesWithSpaceX

CryptoMarketRecovery

US-IranTalksVSTroopBuildup

USStocksHitRecordHighs

WCTCTradingChallengeShare8MUSDT

Pin